MaxCyte, Inc.

$1.55

+$0.00 (+0.00%)

Jan 5, 2026

Price History (1Y)

Analysis

MaxCyte, Inc. is a healthcare company operating in the medical devices industry. The company has a market capitalization of $165.34M and generated revenue of $34.42M (TTM). It employs 114 individuals. The company's financial health is characterized by significant losses. Net income (TTM) was -$45,631,000, with an EBITDA of -$46,208,000. The operating margin was -162.4% and the profit margin was -132.6%. MaxCyte has a cash balance of $105.73M and debt of $18.16M, resulting in a debt to equity ratio of 10.07. MaxCyte's valuation is indicated by a forward P/E ratio of -5.75 and an EV/EBITDA of -1.68. The company has experienced a revenue growth rate of -16.4% (YoY) and does not pay dividends, with a payout ratio of 0.0%.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About MaxCyte, Inc.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Visit website →

Key Statistics

Market Cap
$165.34M
P/E Ratio
N/A
52-Week High
$5.20
52-Week Low
$1.26
Avg Volume
910.83K
Beta
0.36

Company Info

Exchange
NMS
Country
United States
Employees
114